[go: up one dir, main page]

WO2004081045A3 - Vaccin - Google Patents

Vaccin Download PDF

Info

Publication number
WO2004081045A3
WO2004081045A3 PCT/EP2004/002642 EP2004002642W WO2004081045A3 WO 2004081045 A3 WO2004081045 A3 WO 2004081045A3 EP 2004002642 W EP2004002642 W EP 2004002642W WO 2004081045 A3 WO2004081045 A3 WO 2004081045A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunogens
apociii
present
atherosclerosis
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/002642
Other languages
English (en)
Other versions
WO2004081045A2 (fr
Inventor
Pascal Mettens
Philippe Monteyne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of WO2004081045A2 publication Critical patent/WO2004081045A2/fr
Publication of WO2004081045A3 publication Critical patent/WO2004081045A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention, qui a trait à de nouvelles thérapeutiques vaccinales, concerne également des traitements prophylactiques de maladies athéroscléreuses. Elle porte, en outre, sur des fragments spécifiques contenant des agents immunogènes ou sur des dérivés d'alipoprotéine C-III oxydée (ApoCIII). Les vaccins selon l'invention, qui contiennent les agents immunogènes susmentionnés, sont efficaces pour prévenir ou réduire la formation de plaques d'athérosclérose pour une longue durée, réduisant, de ce fait, l'éventualité de la survenue d'une athérosclérose débouchant sur une maladie coronarienne ou cérébro-vasculaire. L'invention concerne aussi des méthodes de traitement ou de prévention de l'athérosclérose et ce, grâce une vaccination, active ou passive, par administration à un patient d'un anticorps à même de se lier aux fragments spécifiques d'ApoCIII. Elle a trait, de surcroît, à des anticorps monoclonaux spécifiques et à leur utilisation dans le traitement de l'athérosclérose ainsi qu'à l'utilisation médicinale des agents immunogènes susmentionnés et à des procédés permettant de les produire. Les fragments d'ApoCIII qui constituent la base de ces agents immunogènes ainsi que les cibles d'une immunothérapie passive se situent dans les acides aminés compris entre les N° 45 et 76 et, notamment 12 et 35 de la forme adulte de l'APOCIII humaine.
PCT/EP2004/002642 2003-03-13 2004-03-11 Vaccin Ceased WO2004081045A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0305793.2 2003-03-13
GB0305793A GB0305793D0 (en) 2003-03-13 2003-03-13 Vaccine

Publications (2)

Publication Number Publication Date
WO2004081045A2 WO2004081045A2 (fr) 2004-09-23
WO2004081045A3 true WO2004081045A3 (fr) 2004-12-29

Family

ID=9954732

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/002642 Ceased WO2004081045A2 (fr) 2003-03-13 2004-03-11 Vaccin

Country Status (2)

Country Link
GB (1) GB0305793D0 (fr)
WO (1) WO2004081045A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
CN106811443A (zh) * 2015-11-27 2017-06-09 西藏自治区人民医院 载脂蛋白c-ⅲ单克隆抗体的制备及应用
MA45602A (fr) 2016-07-08 2019-05-15 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
JP7039694B2 (ja) 2017-10-31 2022-03-22 スターテン・バイオテクノロジー・ベー・フェー 抗ａｐｏｃ３抗体およびその使用方法
EP4368638A3 (fr) * 2020-07-22 2024-07-31 3H Bio. Co., Ltd. Peptide pour agent immunothérapeutique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064008A2 (fr) * 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccins
WO2003020765A2 (fr) * 2001-08-31 2003-03-13 Glaxosmithkline Biologicals S.A. Vaccins
WO2003086326A2 (fr) * 2002-04-05 2003-10-23 The Regents Of The University Of California Peptides de type g destines a ameliorer l'atherosclerose

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064008A2 (fr) * 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccins
WO2003020765A2 (fr) * 2001-08-31 2003-03-13 Glaxosmithkline Biologicals S.A. Vaccins
WO2003086326A2 (fr) * 2002-04-05 2003-10-23 The Regents Of The University Of California Peptides de type g destines a ameliorer l'atherosclerose

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BROWN MATT: "A vaccine against atherosclerosis.", DRUG DISCOVERY TODAY. 1 JUN 2002, vol. 7, no. 11, 1 June 2002 (2002-06-01), pages 588 - 590, XP002287788, ISSN: 1359-6446 *
LIU HAIQUN ET AL: "Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr", JOURNAL OF LIPID RESEARCH, vol. 41, no. 11, November 2000 (2000-11-01), pages 1760 - 1771, XP002287785, ISSN: 0022-2275 *
MAEDA H ET AL: "MOLECULAR CLONING OF A HUMAN APOC-III VARIANT THREONINE 74-ALANINE 74 MUTATION PREVENTS O GLYCOSYLATION", JOURNAL OF LIPID RESEARCH, vol. 28, no. 12, 1984, pages 1405 - 1409, XP002287786, ISSN: 0022-2275 *
MCCONATHY W J ET AL: "Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III", JOURNAL OF LIPID RESEARCH, BETHESDA, MD, US, vol. 33, 1992, pages 995 - 1003, XP002243300, ISSN: 0022-2275 *
NILSSON JAN ET AL: "Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 30, no. 7, December 1997 (1997-12-01), pages 1886 - 1891, XP002287789, ISSN: 0735-1097 *
PALINSKI W ET AL: "Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis", JOURNAL OF INTERNAL MEDICINE, vol. 247, no. 3, March 2000 (2000-03-01), pages 371 - 380, XP002287787, ISSN: 0954-6820 *
VON ECKARDSTEIN A ET AL: "APOLIPOPROTEIN C-III LYS-5-8 GLU IDENTIFICATION OF AN APOLIPOPROTEIN C-III VARIANT IN A FAMILY WITH HYPERALPHALIPOPROTEINEMIA", 1991, JOURNAL OF CLINICAL INVESTIGATION, VOL. 87, NR. 5, PAGE(S) 1724-1731, ISSN: 0021-9738, XP002287790 *

Also Published As

Publication number Publication date
WO2004081045A2 (fr) 2004-09-23
GB0305793D0 (en) 2003-04-16

Similar Documents

Publication Publication Date Title
WO2003020765A3 (fr) Vaccins
WO2001064008A3 (fr) Vaccins
WO2003090686A3 (fr) Utilisation de proteines de choc thermique pour ameliorer l'avantage therapeutique d'une modalite de traitement non vaccinal
HUP0303173A2 (hu) Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok
WO2002034205A3 (fr) Utilisation des proteines du stress pour stimuler la reponse immunitaire
BRPI0610093A2 (pt) composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente
WO2002056907A3 (fr) Jeu ordonne d'antigene moleculaire
JP2004501101A5 (fr)
JP2002544238A5 (fr)
WO2002096350A3 (fr) Composition de peptide immunogene pour la prevention et le traitement de la maladie d'alzheimer
WO2001053457A3 (fr) Vaccins contre certains troubles neurodegeneratifs
WO2004080375A3 (fr) Vaccin
WO2004081045A3 (fr) Vaccin
AU2003263712A1 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
WO2003090687A3 (fr) Utilisation de proteines de choc thermique pour renforcer la reponse immunitaire
WO2003068147A3 (fr) Traitements de la neurotoxicite dans la maladie d'alzheimer
WO2002060435A8 (fr) Cryptotanshinone permettant de prevenir et d'attenuer la maladie d'alzheimer
Pfützner et al. AIT: new avenues in allergen immunotherapy
WO2004081046A3 (fr) Nouvelle composition
WO2004030607A3 (fr) Therapie d'immunisation passive a base peptidique pour le traitement de l'atherosclerose
CA2382336A1 (fr) Vaccins contre des agents infectieux
WO2002034288A3 (fr) Vaccin
JP2013090574A (ja) ペプチドワクチン
WO2002030458A8 (fr) Composition
WO2001030989A3 (fr) Procede de creation de populations divergentes de molecules et de proteines d'acide nucleique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase